Published in final edited form as:

Curr Opin Allergy Clin Immunol. 2009 October ; 9(5): 437–446. doi:10.1097/ACI.0b013e32832e7d36.

Abnormal skin barrier in the etiopathogenesis of atopic dermatitis

Peter M. Elias^a and Matthias Schmuth^b

^aDermatology Service, Veterans Affairs Medical Center, and Department of Dermatology, University of California, San Francisco, California, USA

^bDepartment of Dermatology, Innsbruck Medical University, Innsbruck, Austria

Abstract

Purpose of review—Many recent studies have revealed the key roles played by Th1/Th2 cell dysregulation, IgE production, mast cell hyperactivity, and dendritic cell signaling in the pathogenesis of atopic dermatitis. Accordingly, current therapy has been largely directed towards ameliorating Th2-mediated inflammation and/or pruritus. We will review here emerging evidence that the inflammation in atopic dermatitis results from inherited and acquired insults to the barrier and the therapeutic implications of this new paradigm.

Recent findings—Recent molecular genetic studies have shown a strong association between mutations in *FILAGGRIN* and atopic dermatitis, particularly in Northern Europeans. But additional acquired stressors to the barrier are required to initiate inflammation. Sustained hapten access through a defective barrier stimulates a Th1 → Th2 shift in immunophenotype, which in turn further aggravates the barrier. Secondary *Staphylococcus aureus* colonization not only amplifies inflammation but also further stresses the barrier in atopic dermatitis.

Summary—These results suggest a new ‘outside-to-inside, back to outside’ paradigm for the pathogenesis of atopic dermatitis. This new concept is providing impetus for the development of new categories of ‘barrier repair’ therapy.

Keywords

antimicrobial peptides; atopic dermatitis; barrier function; barrier repair

Introduction

Although both a defective epidermal permeability barrier [1–4] and a propensity to develop secondary infections [5] are well recognized features of atopic dermatitis, it has been widely assumed that these abnormalities reflect consequences of immunologic abnormalities (the historical ‘inside-outside’ view of atopic dermatitis pathogenesis). We and others have long proposed that the permeability barrier abnormality in atopic dermatitis is not merely an epiphenomenon but rather the ‘driver’ of disease activity (‘outside-inside’ view of disease pathogenesis) [6–8], because the extent of the permeability barrier abnormality parallels severity of disease phenotype in atopic dermatitis [1,2,4]; clinically uninvolved skin sites, as well as skin cleared of inflammation for 5 years or less, continue to display barrier abnormalities [2]; emollient therapy comprises effective ancillary therapy [9]; and most importantly, specific replacement therapy, which targets the prominent lipid abnormalities that account for the barrier abnormality in atopic dermatitis [6,9], corrects the barrier abnormality and comprises

effective anti-inflammatory therapy for atopic dermatitis. In this article, we will provide relevant background information about the epidermal barrier; update recent information about inherited defects that are now recognized as underlying atopic dermatitis; link the barrier abnormality to inflammation in atopic dermatitis; explain how certain acquired stressors, including secondary *Staphylococcus aureus* infection, further aggravate atopic dermatitis; and provide a new therapeutic paradigm for atopic dermatitis based on these emerging concepts.

Basis for the permeability barrier in normal skin

The epidermis generates a set of protective and sensor functions (Tables 1 and 2), mediated by its differentiation end product, the stratum corneum [10]. These defensive functions include the permeability barrier, which retards transcutaneous evaporative water loss, allowing survival in a desiccating external environment, and an antimicrobial barrier, while simultaneously encouraging colonization by nonpathogenic 'normal' flora, which resists growth of microbial pathogens [11]. More recently, appreciated biosensory functions clearly place the epidermis as the distal outpost of the nervous system [12], with broad implications for future therapeutic directions.

The stratum corneum comprises a multilayered tissue composed of flattened, anucleate corneocytes, surrounded by multiple, planar lamellar sheets, enriched in ceramides, cholesterol, and free fatty acids (FFAs). It is the localization of these highly hydrophobic lipids within the extracellular domains of the stratum corneum that inhibits water loss [10]. These lipids are delivered to the stratum corneum as their precursors through secretion of the epidermal lamellar body (Fig. 1). This organelle delivers not only lipid precursors (e.g. glucosylceramides, phospholipids, and cholesterol sulfate) but also the enzymes (β -glucocerebrosidase, acidic sphingomyelinase, secretory phospholipase A₂, and steroid sulfate) that generate ceramides and FFAs, which then self-organize into lamellar membranes. In parallel, lamellar body-derived protease/antiproteases that orchestrate the orderly digestion of corneodesmosomes allow corneocyte shedding [13,14] (Fig. 2). Finally, antimicrobial peptides (AMPs) also are delivered to the stratum corneum intercellular domains through secretion of lamellar body contents [15,16].

Inherited barrier abnormalities in atopic dermatitis

On the basis of inherited abnormalities in either serine protease/antiprotease expression or filaggrin (FLG) production, the development of atopic dermatitis is now increasingly linked to primary defects in stratum corneum structure and function (Fig. 2). The most compelling case for the role of excess serine protease activity in the pathogenesis of atopic dermatitis comes from Netherton syndrome, an autosomal recessive disorder due to loss-of-function mutations in serine peptidase inhibitor, Kazal type 5 (*SPINK5*), the gene encoding the serine protease inhibitor, lymphoepithelial Kazal-type trypsin inhibitor (LEKTI) [17]. Netherton syndrome is characterized by severe atopic dermatitis, mucosal atopy, and anaphylactic reactions to food antigens. Residual LEKTI expression in Netherton syndrome correlates inversely with excess serine protease activity within the outer epidermis [18], resulting in a severe permeability barrier defect and dramatic thinning of stratum corneum due to unrestricted, serine protease-dependent degradation of lipid-processing enzymes and corneodesmosome-constituent proteins, respectively [18]. Although several control studies have been found with an increased frequency of single nucleotide polymorphisms (Glu420Lys) in *SPINK5* [17], recent studies cast doubts upon this association. Likewise, a British case-control study [19] describing putative, gain-of-function polymorphisms (AACCAACC vs. AACC) in the 3' region of kallikrein-related peptidase 7 (*KLK7*), which encodes the serine protease, stratum corneum chymotryptic enzyme (*KLK7*), is now disputed. Furthermore, in a recent genetic study [20] involving 2500 atopic dermatitis cases and 10 000 controls, there was no evidence for an

epistatic (additive) interaction between *SPINK5/KLK7* polymorphisms and FLG mutations. Yet, transgenic mice that express human *KLK7* display a severe atopic dermatitis-like dermatosis. Moreover, in experimental animals, a net increase in serine protease activity, achieved by a variety of means, has been shown to compromise barrier function through accelerated degradation of both corneodesmosomes (accounting for flawed stratum corneum integrity) and lipid-processing enzymes [21] (Fig. 2), resulting in a failure to generate ceramides, a characteristic lipid abnormality in atopic dermatitis [22,23].

Elevated serine protease activity likely provokes the barrier abnormality by a second, unrelated mechanism, that is, by signaling of the plasminogen activator type 2 receptor (PAR2), which in turn downregulates lamellar body secretion [24], entombing these organelles in nascent corneocytes [25]. Failure of lamellar body secretion accounts, in turn, for the global decrease in stratum corneum lipids in atopic dermatitis [3,26], which correlates with a decrease in extracellular lamellar bilayers in atopic dermatitis [4]. Thus, increased serine protease activity alone induces abnormalities that parallel those in atopic dermatitis, providing a mechanistic basis for the global reduction in extracellular lipids and further decline in ceramide levels that occur in atopic dermatitis.

The strongest evidence for a primary structural abnormality of stratum corneum underlying the pathogenesis of atopic dermatitis derives from the recent link between loss-of-function mutations in the gene encoding, filament-aggregating protein (FLG), and atopic dermatitis [27,28]. Up to 60% of Europeans with atopic dermatitis reveal single or double-allele mutations in *FLG* on chromosome 1q21. FLG is the main component of F-type keratohyalin granules, responsible for the designation of the stratum granulosum. Decreased FLG expression results in a paucity of keratohyalin granules, a hallmark of ichthyosis vulgaris [29], and reduced FLG is also common in atopic dermatitis [3,30,31]. Accordingly, ichthyosis vulgaris is associated with concomitant atopic dermatitis, allergic rhinitis, and/or asthma in approximately two-thirds of patients [3].

FLG deficiency has been ascribed to both nonsense and frameshift mutations. Although more than 20 different mutations have been reported, six of them are the most common, accounting for the majority of European cases [32,33]. *FLG* mutations result in truncation of pro-FLG, explaining FLG expression in the epidermis of ichthyosis vulgaris/atopic dermatitis. Although heterozygous patients show residual FLG with a milder phenotype, ichthyosis vulgaris patients with homozygous or compound heterozygous mutations lack FLG and exhibit generalized scaling, as well as an increased propensity to develop severe and persistent atopic dermatitis.

The initial product of FLG translation is pro-FLG, a large, histidine-rich, highly cationic phosphoprotein, consisting of 10–12 FLG repeats, enriched in hydrophobic amino acids [34–36]. Pro-FLG contains an amino-terminal sequence, including a calcium-binding A domain; the B domain is a putative S100-like, calcium-binding domain. In contrast to the cytoplasmic localization of C-terminal FLG monomers, the N-terminus of pro-FLG appears to tether to the nucleus via its nuclear localization sequence. In normals, pro-FLG is dephosphorylated and proteolytically processed to FLG monomers during cornification. Processed FLG peptides then induce aggregation of keratins within the corneocyte cytosol and attach to the cornified envelope, a unique structure that replaces the plasma membrane as granular cells transform into corneocytes [37,38]. The cornified envelope provides a relatively inflexible, mechanically resistant barrier. However, as the water content of the stratum corneum drops in the mid-to-outer stratum corneum, FLG detaches from the cornified envelope, and the C-terminal portion of FLG is proteolyzed into its constituent amino acids, followed by their deimination into polycarboxylic acids ('natural moisturizing factors' NMF) [39–41] (Fig. 3).

Link between filaggrin deficiency and barrier dysfunction in atopic dermatitis

Although it is widely hypothesized that FLG deficiency provokes a permeability barrier abnormality [28], the cellular basis for such an abnormality is unknown. Indeed, abnormal permeability barrier function was noted in ichthyosis vulgaris patients, without atopic dermatitis, predating the era of genetic FLG analysis [42–44], but Hubiche *et al.* [45] failed to find defective barrier function in ichthyosis vulgaris, thereby challenging the prevailing hypothesis that FLG deficiency causes an impaired barrier to transcutaneous water loss. Yet, how loss of FLG (an intracellular protein) could provoke a permeability barrier abnormality (almost always an extracellular defect) is not clear. Loss of this quantitatively important protein could alter corneocyte shape, perhaps inducing flattening, that could disrupt extracellular lamellar bilayer organization. Our very recent studies suggest that unprocessed pro-FLG could interfere with lamellar body secretion [46]. As noted above, pro-FLG is proteolytically processed into FLG during the abrupt transition from the granular layer into stratum corneum and is itself proteolytically degraded into amino acids, which are further deaminated into polycarboxylic acids such as pyrrolidine carboxylic acid and *trans*-urocanic acid (*t*-UCA) [47]. These metabolites, in turn, act as osmolytes, drawing water into corneocytes, thereby accounting in large part for corneocyte hydration. Hence, the most immediate result of FLG deficiency in atopic dermatitis is decreased stratum corneum hydration, leading in turn to a steeper water gradient across the stratum corneum, which likely ‘drives’ increased transcutaneous water loss. Thus, decreased stratum corneum hydration, leading to increased water loss, is the first and most obvious cause of barrier dysfunction in FLG-deficient atopic dermatitis.

Neither corneocyte flattening nor decreased stratum corneum hydration alone would suffice, however, to enhance antigen penetration, which is best explained by another (fourth) consequence of FLG deficiency, that is, decreased downstream production of acidic metabolites resulting from FLG proteolysis. Indeed, *t*-UCA, in particular, is a purported, endogenous acidifier of the stratum corneum [48]. Thus, decreased generation of FLG products could result in an initial increase in the stratum corneum pH, sufficient to activate multiple serine protease in stratum corneum, which all exhibit neutral-to-alkaline pH optima [14]. Such a pH-induced increase in serine protease activity, if prolonged, could precipitate downstream structural and functional alterations [10].

Basis for inflammation in atopic dermatitis

One important downstream consequence of increased serine protease activity is generation of the primary cytokines, IL-1 α and IL-1 β [49], from their 33 kDa pro-forms, which are stored in large quantities in the cytosol of corneocytes. The putative pH-induced increase in serine protease activity would generate 17 kDa active forms of these cytokines [49]; the first step in the cytokine cascade that we propose is an important contributor to inflammation in atopic dermatitis [6,7]. Sustained antigen ingress through a defective barrier leading to a Th2-dominant infiltrate then is a second cause of inflammation in atopic dermatitis [41] (Figs 3 and 4). Certain antigens, such as cat dander, mites, and cockroach antigens, are preferentially associated with atopic dermatitis and are frequent triggers of atopic dermatitis, particularly in FLG-deficient patients [50]. Mites themselves activate serine protease activity with further damage to the barrier [51]. Yet, the damaged barrier in atopic dermatitis is due to lipid depletion, explaining the preferential penetration of water-soluble haptens, such as nickel, in atopic dermatitis [52]. Accordingly, correction of the barrier abnormality alone should ameliorate both the cytokine cascade and allergen-induced inflammation in atopic dermatitis.

Other contributors to broad barrier failure in atopic dermatitis

Similar to permeability barrier dysfunction, the antimicrobial barrier is compromised in atopic dermatitis, commonly leading to colonization of lesional and nonlesional skin by *S. aureus*

[5]. Impetiginization, widespread folliculitis, or less frequently, cutaneous abscesses or cellulitis are well recognized complications in atopic dermatitis (Fig. 5). Colonization by superantigen-producing *S. aureus* strains is more common in steroid-resistant patients [53] and further exacerbates disease in severe atopic dermatitis through augmentation of IgE production, as well as through development of specific IgE directed towards staphylococcal exotoxins (rev. in [19]). In addition, patients with atopic dermatitis are also susceptible to widespread cutaneous viral infections, including molluscum contagiosum, herpes simplex (Kaposi's varicelliform eruption), and life-threatening vaccinia. Widespread dermatophytosis (tinea corporis) and *Malassezia* infections also occur in atopic dermatitis, and the latter can stimulate specific IgE production. Together, these observations point to loss of a competent antimicrobial barrier in atopic dermatitis. Although failure of both permeability and antimicrobial function is well recognized in atopic dermatitis, only recently has it become clear that these two functions share common structural and biochemical features [11] and both are coregulated and interdependent [54•]. Thus, failure of the permeability barrier in itself favors secondary infection, and conversely, pathogen colonization/infection further aggravates the permeability barrier abnormality.

In the prior sections, we discussed first how genetic and acquired factors can converge to provoke or amplify atopic dermatitis, and second, how inflammation can be attributed both to an epidermis-derived cytokine cascade, as well as to stimulation of a Th2-dominant inflammatory infiltrate due to sustained antigen ingress. Increased colonization with *S. aureus* [55] occurs both as a result of the barrier abnormality (a structurally competent, lipid-replete, acidic stratum corneum, which itself comprises a formidable barrier to pathogen colonization) [11], and *S. aureus* can further aggravate barrier function in atopic dermatitis by several mechanisms. The antimicrobial barrier is intimately linked to the permeability barrier [54•], and as with water egress, pathogen ingress occurs via the extracellular domains [56]. Moreover, an impaired permeability barrier alone predisposes to pathogen colonization, not only because of the increase in surface pH but also because levels of FFA and the ceramides metabolite, sphingosine, which exhibit potent antimicrobial activity [56,57], are reduced in atopic dermatitis [11]. Surface proteins on *S. aureus* can down-regulate epidermal FFA production, thereby aggravating both permeability and antimicrobial function in parallel, a strategy that could also facilitate microbial invasion. In addition, members of two key families of AMPs, the human cathelicidin product (hCAP), cathelicidin (LL-37), and human β -defensins (hBDs) 2 and 3, are downregulated in a Th2-dependent fashion in atopic dermatitis [55,58]. Notably, both the hCAP aminoterminal fragment, LL-37, and hBD3 display robust activity against *S. aureus*. LL-37 is required for normal epidermal permeability barrier function [54•] (notably, LL-37 is also important for the integrity of extracutaneous epithelia). Thus, it is likely that decreased LL-37 amplifies the barrier defect in atopic dermatitis.

Over time, nontoxigenic strains of *S. aureus* that colonize atopic dermatitis can be replaced by enterotoxin-generating strains [59], which in turn, could aggravate atopic dermatitis by at least three mechanisms (Fig. 5): toxigenic strains are more likely to produce clinical infections than are nontoxigenic strains [59]; some toxins stimulate pruritus [60] and production of specific IgE [5,61]; and some toxins serve as 'superantigens' that stimulate T and B-cell proliferation, as well as immunoglobulin class switching to allergen-specific or 'superallergens' that stimulate IgE production [5]. Activated T cells produce IL-31, which also induces pruritus [62]. Finally, clinical infections, particularly folliculitis, are notoriously pruritic, even in nonatopics, eliciting an 'itch-scratch' vicious cycle that creates additional portals of entry for pathogens. It is self-evident that excoriations create further defects in the permeability barrier, representing yet another potentially important vicious cycle in atopic dermatitis pathogenesis.

Finally, several other critical defensive functions of the stratum corneum are also compromised in atopic dermatitis, including (Table 1) stratum corneum integrity (cohesion), reflected by

excess scale (abnormal desquamation), and diminished stratum corneum hydration, reflected by life-long cutaneous xerosis in these patients, even after overt inflammation recedes [2]. Similar to the defective permeability and antimicrobial barriers, stratum corneum hydration declines in both lesional and nonlesional atopic dermatitis skin, with its severity paralleling disease activity [1,4]. Decreased stratum corneum hydration is not merely of cosmetic concern, because it alone suffices to stimulate epidermal hyperplasia and early evidence of inflammation, such as mast cell degranulation, even in normal skin. Whether additional defensive functions of the stratum corneum, such as antioxidant or ultraviolet defense, also fail in atopic dermatitis remains unknown. Nevertheless, atopic dermatitis can be viewed as a disease of broad barrier failure.

Exogenous and endogenous stressors further aggravate barrier function in atopic dermatitis

That *FLG* mutations alone do not suffice is shown in ichthyosis vulgaris, in which the same single or double-allele *FLG* mutations reduce FLG content, but inflammation (i.e. atopic dermatitis) does not always occur. Certain stressors could elicit disease by aggravating the barrier abnormality by provoking an incremental increase in pH of the stratum corneum, leading to a further amplification of serine protease activity (Fig. 3). Acquired pH-dependent increases in serine protease activity likely accounts for the precipitation of atopic dermatitis following the use of neutral-to-alkaline soaps [63].

Prolonged exposure to a reduced environmental humidity, as occurs in radiant-heated homes in temperate climates during the winter, is also a well known risk factor for atopic dermatitis. Under these conditions, transcutaneous water loss would accelerate across a defective stratum corneum, aggravating the underlying permeability barrier abnormality and amplifying cytokine signaling of inflammation. Because FLG proteolysis is regulated by changes in external humidity [47], sustained reductions in environmental relative humidities could further deplete residual FLG in single-allele *FLG*-deficient patients. Finally, sustained psychological stress aggravates permeability barrier function in humans [64], and psychological stress is both a well known precipitant of atopic dermatitis and cause of resistance to therapy. In experimental animals, psychological stress induces an increase in endogenous glucocorticoids, which in turn alter permeability barrier homeostasis, stratum corneum integrity, and epidermal antimicrobial defense (Fig. 3). The putative mechanism for the negative effects of psychological stress is glucocorticoids-mediated inhibition of synthesis of the three key epidermal lipids that mediate barrier function, that is, ceramides, cholesterol, and FFA. Accordingly, a topical mixture of these three lipids largely normalizes all of these functions, even in the face of ongoing psychological stress or glucocorticoids therapy, and should comprise particularly effective therapy for atopic dermatitis patients with unusual levels of stress (see also below).

'Outside-inside,' then back to 'outside' pathogenic mechanisms in atopic dermatitis

Despite accumulating evidence in support of a barrier-initiated pathogenesis of atopic dermatitis, recent studies suggest specific mechanisms whereby Th2-generated cytokines could also further aggravate atopic dermatitis [41]. Exogenous applications of the Th2 cytokine, IL-4, impede permeability barrier recovery after acute perturbations [65]. The basis for the negative effects of IL-4 could include (Fig. 6): inhibition of ceramide synthesis [66], providing yet another mechanism accounting for decreased ceramide in atopic dermatitis; inhibition of keratinocyte differentiation-linked proteins, most notably loricrin and FLG [30]; and decreased desmoglein 3 expression, which would further compromise stratum corneum integrity. In a further 'vicious cycle,' serum IgE from atopic dermatitis patients autoreacts against a variety of keratinocyte antigens [67]. Together, these observations provide acquired mechanisms that could further compromise barrier function in atopic dermatitis [30]. Thus, primary inherited

barrier abnormalities in atopic dermatitis ultimately stimulate downstream paracrine mechanisms that could further compromise permeability barrier function, completing a potential 'outside-inside-outside' pathogenic loop in atopic dermatitis (Fig. 6). Measures aimed at barrier repair should prevent and/or ameliorate the inflammatory disease component in atopic dermatitis and could break the vicious cycle of inflammation-induced barrier impairment [30].

Therapeutic implications

Together, the converging pathogenic features described above create a strong rationale for the deployment of specific strategies to restore barrier function in atopic dermatitis. On the basis of the mechanisms described above, these approaches could range from a prolonged reduction in the pH of stratum corneum alone (hyperacidification), applications of serine protease inhibitors, topical PAR2 antagonists, general moisturization measures, or specific lipid replacement therapy. Although topical application of α 1-antitrypsin was evaluated in Netherton syndrome [68], no therapeutic efficacy was observed. Nevertheless, it is still possible that reducing the protease activator could be useful in atopic dermatitis. Moisturizers are widely used in atopic dermatitis, and when used under nursing supervision, have been shown to reduce topical steroid usage. Two clinical studies support the efficacy of targeted, ceramide-dominant, triple-lipid replacement therapy in atopic dermatitis. An open-label study [4] demonstrated dramatic improvements in clinical activity, permeability barrier function, and stratum corneum integrity in children with severe, recalcitrant atopic dermatitis with an over-the-counter version of this technology (TriCeram; Osmotics Corp., St. Denver, Colorado, USA). More recently, a higher strength, US Food and Drug Administration (FDA)-approved prescription formulation (EpiCeram cream; Promius Pharmaceuticals, Bridgewater, New Jersey, USA) (Dr Elias is a coinventor of this University of California-patented technology. He is a consultant for Promius Pharmaceuticals, which markets EpiCeram in the United States) demonstrated efficacy that was comparable to a mid-potency steroid (fluticasone, Cutivate cream; GlaxoSmithKline, Middlesex, UK) in an investigator-blinded, multicenter clinical trial of pediatric patients with moderate-to-severe atopic dermatitis [69] (Table 3).

Conclusion

As prior studies revealed the key roles played by Th1/Th2 cell dysregulation in the evolution of atopic dermatitis, until recently current therapy has been directed largely at ameliorating Th2-mediated inflammation and pruritus. We have reviewed here emerging evidence that the inflammation in atopic dermatitis results from inherited and acquired insults to the barrier and the therapeutic implications of this new paradigm. Moreover, these preliminary, recent studies suggest that pathogenesis-based therapy is effective and could comprise a new paradigm for the therapy of atopic dermatitis. Yet, an important question remains: will restoration of permeability barrier function alone simultaneously improve antimicrobial defense in atopic dermatitis? As recent studies have shown that these two key functions are both regulated in parallel and interdependent [54•], there is reason to be optimistic on this score, as well. A final consequence of the defective epidermal barrier in atopic dermatitis could be that it would allow epicutaneous delivery of antigens that induce asthma and allergic rhinitis. Thus, the 'atopic march', that is, the tendency for atopic dermatitis to precede the later development of mucosal atopy, can be explained by cutaneous penetration of aeroallergens of all types. FLG deficiency is associated with mucosal atopy, independent of atopic dermatitis [70], although FLG is not expressed in either bronchial or other nonkeratinizing mucosal epithelia [71]. An implication of this observation is that again barrier repair therapy could block development of the 'atopic march'.

Acknowledgments

We gratefully acknowledge the superb editorial assistance of Ms Joan Wakefield, including her preparation of the graphics. This work was supported by National Institutes of Health (NIH) grant #AR019098, Department of Defense (DOD) grant #W81XWH-05-2-0094, and the Medical Research Service, Department of Veterans Affairs.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- • of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 000-000).

1. Sugarman JL, Fluhr JW, Fowler AJ, et al. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. *Arch Dermatol* 2003;139:1417–1422. [PubMed: 14623701]
2. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. *Acta Derm Venereol* 1995;75:429–433. [PubMed: 8651017]
3. Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. *J Dermatol Sci* 2006;43:159–169. [PubMed: 16887338]
4. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. *J Am Acad Dermatol* 2002;47:198–208. [PubMed: 12140465]
5. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol* 2006;144:1–9. [PubMed: 16542358]
6. Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. *Am J Contact Dermat* 1999;10:119–126. [PubMed: 10444104]
7. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. *Arch Dermatol* 2001;137:1079–1081. [PubMed: 11493102]
8. Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. *Contact Dermatitis* 1999;41:177–180. [PubMed: 10515093]
9. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology* 2007;214:61–67. [PubMed: 17191050]
10. Elias PM. Stratum corneum defensive functions: an integrated view. *J Invest Dermatol* 2005;125:183–200. [PubMed: 16098026]
11. Elias PM. The skin barrier as an innate immune element. *Sem Immunopath* 2007;29:3–14.
12. Denda M, Nakatani M, Ikeyama K, et al. Epidermal keratinocytes as the forefront of the sensory system. *Exp Dermatol* 2007;16:157–161. [PubMed: 17286806]
13. Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. *J Invest Dermatol* 2004;122:1235–1244. [PubMed: 15140227]
14. Brattsand M, Stefansson K, Lundh C, et al. A proteolytic cascade of kallikreins in the stratum corneum. *J Invest Dermatol* 2005;124:198–203. [PubMed: 15654974]
15. Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. *J Invest Dermatol* 2005;124:394–400. [PubMed: 15675959]

16. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, beta-defensin 2 is packaged in lamellar bodies. *Exp Mol Pathol* 2003;74:180–182. [PubMed: 12710950]
17. Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. *Nat Genet* 2001;29:175–178. [PubMed: 11544479]
18. Hachem JP, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. *J Invest Dermatol* 2006;126:1609–1621. [PubMed: 16601670]
19. Vasilopoulos Y, Cork MJ, Murphy R, et al. Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. *J Invest Dermatol* 2004;123:62–66. [PubMed: 15191543]
20. Weidinger S, Baurecht H, Wagenpfeil S, et al. Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. *J Allergy Clin Immunol* 2008;122:560e4–568e4. [PubMed: 18774391]
21. Hachem JP, Crumrine D, Fluhr J, et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. *J Invest Dermatol* 2003;121:345–353. [PubMed: 12880427]
22. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. *Acta Derm Venereol* 1998;78:27–30. [PubMed: 9498022]
23. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? *J Invest Dermatol* 1991;96:523–526. [PubMed: 2007790]
24. Hachem JP, Houben E, Crumrine D, et al. Serine protease signaling of epidermal permeability barrier homeostasis. *J Invest Dermatol* 2006;126:2074–2086. [PubMed: 16691196]
25. Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. *J Invest Dermatol* 2008;128:370–377. [PubMed: 17713572]
26. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. *J Am Acad Dermatol* 2003;48:352–358. [PubMed: 12637914]
27. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. *J Invest Dermatol* 2006;126:1200–1202. [PubMed: 16702964]
28. Hudson TJ. Skin barrier function and allergic risk. *Nat Genet* 2006;38:399–400. [PubMed: 16570058]
29. Fleckman P, Brumbaugh S. Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris. *Exp Dermatol* 2002;11:327–336. [PubMed: 12190941]
30. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol* 2007;120:150–155. [PubMed: 17512043]
31. Bieber T. Atopic dermatitis. *N Engl J Med* 2008;358:1483–1494. [PubMed: 18385500]
32. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. *J Allergy Clin Immunol* 2008;122:689–693. [PubMed: 18774165]
33. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. *J Invest Dermatol* 2007;127:1282–1284. [PubMed: 17502856]
34. Lynley AM, Dale BA. The characterization of human epidermal filaggrin: a histidine-rich, keratin filament-aggregating protein. *Biochim Biophys Acta* 1983;744:28–35. [PubMed: 6187370]
35. Harding CR, Scott IR. Histidine-rich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation. *J Mol Biol* 1983;170:651–673. [PubMed: 6195345]
36. Fleckman P, Dale BA, Holbrook KA. Profilaggrin a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. *J Invest Dermatol* 1985;85:507–512. [PubMed: 3905974]
37. Takahashi M, Tezuka T, Katunuma N. Filaggrin linker segment peptide and cystatin alpha are parts of a complex of the cornified envelope of epidermis. *Arch Biochem Biophys* 1996;329:123–126. [PubMed: 8619628]

38. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isopeptide cross-linked components of the human epidermal cornified cell envelope. *J Biol Chem* 1995;270:17702–17711. [PubMed: 7543090]
39. Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules: source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. *Biochim Biophys Acta* 1982;719:110–117. [PubMed: 7171620]
40. Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. *J Invest Dermatol* 1994;103:731–741. [PubMed: 7963664]
41. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. *J Allergy Clin Immunol* 2008;121:1337–1343. [PubMed: 18329087]
42. Abe T, Ohkido M, Yamamoto K. Studies on skin surface barrier functions: skin surface lipids and transepidermal water loss in atopic skin during childhood. *J Dermatol* 1978;5:223–229. [PubMed: 361786]
43. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. *Acta Derm Venereol* 1985;65:102–105. [PubMed: 2408409]
44. Fartasch M, Diepgen TL. The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? *Acta Derm Venereol Suppl (Stockh)* 1992;176:26–31. [PubMed: 1476030]
45. Hubiche T, Ged C, Benard A, et al. Analysis of SPINK 5, KLK 7 and FLG genotypes in a french atopic dermatitis cohort. *Acta Derm Venereol* 2007;87:499–505. [PubMed: 17989887]
46. Scharschmidt T, Man MQ, Hatano Y, et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. *J Allergy Clin Immunol*. (in press).
47. Scott IR, Harding CR. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. *Dev Biol* 1986;115:84–92. [PubMed: 3516761]
48. Krien P, Kermici M. Evidence for the existence of a self-regulated enzymatic process within human stratum corneum—an unexpected role for urocanic acid. *J Invest Dermatol* 2000;115:414–420. [PubMed: 10951277]
49. Nylander-Lundqvist E, Back O, Egelrud T. IL-1 beta activation in human epidermis. *J Immunol* 1996;157:1699–1704. [PubMed: 8759758]
50. Bisgaard H, Simpson A, Palmer CN, et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. *PLoS Med* 2008;5:e131. [PubMed: 18578563]
51. Jeong SK, Kim HJ, Youm JK, et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. *J Invest Dermatol* 2008;128:1930–1939. [PubMed: 18305573]
52. Novak N, Baurecht H, Schafer T, et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. *J Invest Dermatol* 2008;128:1430–1435. [PubMed: 18049447]
53. Schlievert PM, Case LC, Strandberg KL, et al. Superantigen profile of *Staphylococcus aureus* isolates from patients with steroid-resistant atopic dermatitis. *Clin Infect Dis* 2008;46:1562–1567. [PubMed: 18419342]
54. Aberg KM, Man MQ, Gallo RL, et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. *J Invest Dermatol* 2008;128:917–925. [PubMed: 17943185]
This study demonstrates that permeability and antimicrobial barriers are coordinately regulated by permeability barrier requirements, and cathelin-related antimicrobial peptide (CRAMP) is required for permeability barrier homeostasis.
55. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* 2002;347:1151–1160. [PubMed: 12374875]
56. Miller SJ, Aly R, Shinefeld HR, Elias PM. In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. *Arch Dermatol* 1988;124:209–215. [PubMed: 3341800]
57. Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphingosines. *J Invest Dermatol* 1992;98:269–273. [PubMed: 1545135]

58. Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol* 2003;171:3262–3269. [PubMed: 12960356]
59. Lomholt H, Andersen KE, Kilian M. Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. *J Invest Dermatol* 2005;125:977–982. [PubMed: 16297199]
60. Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. *Br J Dermatol* 2001;145:302–305. [PubMed: 11531797]
61. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis: evidence for a new group of allergens. *J Clin Invest* 1993;92:1374–1380. [PubMed: 7690780]
62. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* 2006;117:411–417. [PubMed: 16461142]
63. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. *J Allergy Clin Immunol* 2006;118:3–21. quiz 22–23. [PubMed: 16815133]
64. Garg A, Chren MM, Sands LP, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. *Arch Dermatol* 2001;137:53–59. [PubMed: 11176661]
65. Kurahashi R, Hatano Y, Katagiri K. IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. *J Invest Dermatol* 2008;128:1329–1331. [PubMed: 17960173]
66. Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. *J Invest Dermatol* 2005;124:786–792. [PubMed: 15816837]
67. Altrichter S, Kriehuber E, Moser J, et al. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. *J Invest Dermatol* 2008;128:2232–2239. [PubMed: 18480840]
68. Mazereeuw-Hautier J, Cope J, Ong C, et al. Topical recombinant alpha1-antitrypsin: a potential treatment for Netherton syndrome? *Arch Dermatol* 2006;142:396–398. [PubMed: 16549727]
69. Sugarman J, Parish L. Efficacy of a lipid-based, barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. *Pediatr Dermatol*. (in press).
70. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. *Nature* 2008;454:445–454. [PubMed: 18650915]
71. De Benedetto A, Qualia CM, Baroody FM, Beck LA. Filaggrin expression in oral, nasal, and esophageal mucosa. *J Invest Dermatol* 2008;128:1594–1597. [PubMed: 18172455]

Figure 1. Lamellar body secretion codelivers key components of both permeability and antimicrobial barriers
hBD2, human- β -defensin 2; LL-37, cathelicidin. Modified from Elias [11].

Figure 2. Abnormal maturation of stratum corneum lamellar membranes results in decreased ceramides in atopic dermatitis

β-GlcCer'ase, β-glucocerebrosidase; hBD2, human-β-defensin 2; LL-37, cathelicidin; SM'ase, acidic sphingomyelinase; sPLA2, secretory phospholipase A2.

Figure 3. Convergence of inherited and acquired mechanisms activate serine proteases, impacting multiple stratum corneum functions, but by divergent mechanisms

DSG, desmoglein; FLG, filaggrin; LEKTI, lymphoepithelial Kazal-type trypsin inhibitor; PAR2, plasminogen activator receptor, type 2; SPI, serine protease inhibitor. Modified from Elias *et al.* [41].

Figure 5. Secondary infections further aggravate barrier abnormality in atopic dermatitis
Modified from Elias *et al.* [41].

Figure 6. 'Outside-inside' initial provocation of atopic dermatitis eventually leads to 'outside-inside-outside' vicious cycle by multiple mechanisms

Cer, ceramides; FLG, filaggrin; hBD2, human- β -defensin 2; NGF, nerve growth factor.

Modified from Elias *et al.* [41].

Table 1

Defensive functions of the stratum corneum

Function	Localization	Structural basis	Biochemical basis	Abnormal in atopic dermatitis
Permeability barrier + xenobiotic penetration	Extracellular matrix	Lamellar bilayers	Cer:Chol:FFA (1:1 :1)	Yes
Antimicrobial defense	Extracellular matrix	Lamellar bilayers	LL-37, hBD2	Yes
	? Corneocyte cytosol	?	?RNase7, psoriasin	No
Cohesion/desquamation	Extracellular matrix	Corneodesmosomes	Protease/antiprotease; cholesterol sulfate	Yes
Mechanical/rigidity	Corneocyte	Cornified envelope	Isopeptide (γ -glutamyl x-linking), Ca^{++}	?
Hydration	Corneocyte	Corneocyte lipid envelope	ω -OH-ceramides	Yes
	Extracellular matrix	Sebaceous glands	TG $\rightarrow$ Glycerol	?
	Basal keratinocyte	Plasma membrane	AQP3 channel	?
UV defense	Corneocyte cytosol	–	FLG $\rightarrow$ UCA	?
Antioxidant defense	Skin surface	Sebaceous glands	Vitamin E, CoQ	Yes
	Extracellular matrix			?

?, not known; AQP, aquaporin; Cer, ceramides; chol, cholesterol; CoQ, coenzyme Q; FFAs, free fatty acids; FLG, filaggrin; hBD2, human- β -defensin 2; LL-37, cathelicidin; UCA, urocanic acid; UV, ultraviolet.

Table 2

Shared structural and biochemical features of permeability and antimicrobial barriers

Feature	Permeability barrier	Antimicrobial barrier
Cohesive stratum corneum	+	+
Replete lamellar matrix	+	+
Low H ₂ O content of stratum corneum	+	+
Acidic pH of stratum corneum	+	+
Stratum corneum extracellular lipids (e.g. FFAs)	+	+
Secreted epidermal AMP (e.g. LL-37)	+	+
Secreted protease inhibitors	+	+
Normal microbial flora	?	+

FFAs, free fatty acids; LL-37, cathelicidin.

Table 3

Efficacy of EpiCeram emulsion in comparison with mid-strength steroid in moderate-to-severe childhood atopic dermatitis

Comparable ↓ SCORAD scores
Comparable ↓ reduction of itch
Comparable improvement in sleep habits
Comparable percentage of patients 'clear or almost clear' by Physicians' Global Assessment

SCORAD, SCORing Atopic Dermatitis. Sugarman and Parish [69].